Technology | 2019.10.23
ImpediMed Announces Ambitious New Program Aimed at Ending Cancer-Related Lymphedema
CARLSBAD, Calif. and BRISBANE, Australia, Oct. 23, 2019 /PRNewswire/ -- ImpediMed Limited (ASX: IPD), a global provider of medical technology to non-invasively measure, monitor and manage tissue composition and fluid status using bioimpedance spectroscopy (BIS), today announces the...
For more information, please visit
https://www.prnewswire.com:443/news-rele[...]ated-lymphedema-300943600.html
